Insights

Panelists discuss how current third-line treatment options for metastatic colorectal cancer, including regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, are selected based on patient-specific factors, safety profiles, and treatment goals, while also exploring future directions and unmet needs in mCRC management.

Elizabeth O’Donnell, MD, discusses how recent clinical trial findings are reshaping frontline treatment strategies for transplant-ineligible patients with newly diagnosed multiple myeloma, emphasizing the importance of patient-specific factors in therapy selection.

Furthermore, Douglas Sborov, MD, discusses how recent advancements in clinical trials and treatment strategies are reshaping the management of newly diagnosed multiple myeloma patients who are eligible for transplant.

Thomas Powles, MBBS, MRCP, MD, discusses currently available treatment options for previously untreated locally advanced and metastatic urothelial cancer. He presents a hypothetical clinical scenario and discusses his treatment approach to illustrate how he incorporates recent data into his clinical practice.

Margaret Kasner, MD, and Christian Fidler, MD, discuss how effective management of secondary acute myeloid leukemia (AML) in community settings requires early diagnosis, accurate risk stratification, timely referrals, personalized treatment approaches, robust supportive care, and close collaboration with academic centers to ensure optimal patient outcomes.

Panelists discuss how targeted therapies and effective management of adverse events, particularly in relation to the PI3K/AKT/PTEN pathway, are crucial for optimizing treatment outcomes in hormone receptor (HR)–positive, HER2-negative advanced breast cancer.

Nitin Jain, MD, and Joanna M. Rhodes, MD, MDCS, discuss how various aspects of chronic lymphocytic leukemia (CLL) management are approached, including treatment selection based on prior therapies and patient factors, the use of novel agents such as pirtobrutinib, strategies for relapsed/refractory (R/R) disease, treatment sequencing, and the role of multidisciplinary teams in optimizing patient care and outcomes.

Panelists discuss how recent advances in treating Lower-Risk Myelodysplastic Syndromes have impacted clinical practice, using hypothetical scenarios to demonstrate their approach to incorporating new data into patient care.

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Hope Rugo, MD, FASCO and Aditya Bardia MD, MPH, FASCOexplore strategies for managing antibody drug conjugate (ADC)-related toxicities in breast cancer, covering current ADCs, real-world management practices, and future directions, in this OncLive Insights video series.

This educational program, led by experts Shernan Holtan, MD, and Haris Ali, MD, explores the latest strategies and emerging treatments for optimizing management of chronic graft-vs-host disease (cGVHD), including monitoring techniques, therapeutic options, and patient-reported outcomes.

A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.

Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD, Leading experts in relapsed/refractory multiple myeloma, explore evolving treatment landscapes, including CAR T-cell therapies, the role of selinexor, and optimized sequencing strategies, while addressing two complex clinical scenarios and providing key insights for community oncologists to enhance patient care.

Experts on adolescent and young adult acute lymphoblastic leukemia review patient cases have a comprehensive discussion on treatment practices and the evolving therapeutic landscape.

Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.

Hannah Choe, MD discusses the role of the CSF-1 receptor (CSF-1R) pathway in the pathogenesis of graft-versus-host disease (GVHD) and other diseases. She reviews the rationale for targeting this pathway as a therapeutic strategy and examines preclinical and clinical data on the use of CSF-1R inhibitors, such as axatilimab, for the treatment of GVHD. Dr. Choe provides insights on the practical considerations for integrating these novel agents into clinical practice.

Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, examine the role of androgen receptor inhibitors, emphasize the significance of early intervention and biomarkers, and evaluate recent developments in the treatment paradigm for castration-sensitive prostate cancer.

A panel of experts on chronic lymphocytic leukemia review patient cases, discuss the latest research presented at ASCO 2024 and surrounding meetings, and provide insights on evolving clinical practices.

Martin H. Voss, MD, and Moshe Ornstein, MD, explore non-clear cell renal cell carcinoma and the potential impact of clinical trials on the evolution of treatment approaches.

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the evolving landscape of HR+/HER2- metastatic breast cancer management, focusing on the clinical implications of ESR1 and PIK3CA mutations, the role of biomarker testing, the impact of novel therapies and combination strategies, and the importance of personalized treatment approaches in improving patient outcomes.

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, provide valuable insights into targeting the PI3K/AKT/PTEN pathway, exploring mechanisms of resistance, adverse event profiles, and treatment decision-making strategies for patients with HR+/HER2- locally advanced and metastatic breast cancer.

Nathalie Albert, MD, and Matthias Preusser, MD, explore the latest advancements in neuroimaging technologies and techniques, focusing on the use of amino acid tracers to enhance the diagnosis, treatment, and overall care of patients with glioblastoma.

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, explore the current treatment landscape for HER2-positive metastatic breast cancer. They discuss standard of care therapies across lines, pivotal trial data, management of brain metastases, optimal sequencing strategies after, and emerging novel agents. Two patient cases help illustrate real-world decision-making.

Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, provide comprehensive insights on the integration of hepatic artery infusion therapy into clinical practice for patients with colorectal cancer liver metastases and intrahepatic cholangiocarcinoma.

Insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors. Renowned experts Dr. Vivek Subbiah, Dr. Karisa Schreck, and Dr. Rimas Lukas delve into pivotal clinical cases showcasing the identification and targeted treatment of BRAF and RET fusions. The in-depth discussion spotlights practical strategies for NGS testing, overcoming barriers to adoption, efficacy and safety data from landmark trials, sequencing of therapies, and the evolving landscape of precision oncology beyond current approvals. Gain invaluable clinical pearls for optimizing patient outcomes with tumor agnostic targeted agents in the community setting.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.

Funding supported by Taiho Oncology. Content independently developed by OncLive.

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide a comprehensive analysis of risk stratification in high-risk HR+/HER2- early-stage breast cancer, clinical approaches with high-risk breast cancer, recent trial data with CDK4/6 inhibitors, and strategies for managing toxicities for treatment continuity in the management of HR+/HER2- early-stage breast cancer, offering valuable insights to optimize patient care.

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss the nuanced treatment landscape of myelofibrosis, exploring the latest advancements in JAK inhibitors, the importance of individualized care, and the potential of emerging combination therapies to enhance patient outcomes.

Hana Safah, MD, and Corey Cutler, MD, MPH, review recent data in graft-vs-host disease and provide comprehensive insights on treatment practices.

Shirish Gadgeel, MD, and Benjamin Levy, MD, discuss recent updates in 2023 on antibody-drug conjugates for treating patients with advanced NSCLC as well as their clinical implications.